← Eichor
Study identifier: NCT05855941 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

Condition: Cervix Cancer · Endometrial Cancer · Epithelial Ovarian Cancer  ·  Sponsor: Region Västerbotten

PhaseN/A
Planned participants120
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: * Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will * Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.

This description comes directly from the study's public registry record.

Talk to the study team

Erika Figaro  ·  +46907850499  ·  erika.figaro@regionvasterbotten.se

Sara Strandberg, MD, PhD  ·  +46907850000  ·  sara.strandberg@umu.se

Always discuss trial participation with your own doctor first.

Locations (1)

Centre for Gynecology and Obstetrics, Umea University HospitalUmeå, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05855941